Kura Oncology (KURA)
(Delayed Data from NSDQ)
$22.17 USD
-0.81 (-3.52%)
Updated May 17, 2024 04:00 PM ET
After-Market: $22.20 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KURA 22.17 -0.81(-3.52%)
Will KURA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KURA
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
What Makes Kura Oncology (KURA) a New Buy Stock
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Other News for KURA
KURA January 2025 Options Begin Trading
Buy Rating Affirmed for Kura Oncology Amidst Positive Developments and Strong Trial Progress
Buy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic Advantages
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML